2024
413-P: Comparative Effectiveness of Glucose-Lowering Agents on Kidney Outcomes in Adults with Type 2 Diabetes at Moderate Cardiovascular Risk
NEUMILLER J, HERRIN J, SWARNA K, POLLEY E, GALINDO R, UMPIERREZ G, DENG Y, MICKELSON M, MCCOY R. 413-P: Comparative Effectiveness of Glucose-Lowering Agents on Kidney Outcomes in Adults with Type 2 Diabetes at Moderate Cardiovascular Risk. Diabetes 2024, 73 DOI: 10.2337/db24-413-p.Peer-Reviewed Original ResearchPatient-Centered Outcomes Research InstituteModerate CVD riskKidney composite outcomeAssociated with lower riskGLP-1RACVD riskType 2 diabetesKidney outcomesComposite outcomeKidney diseaseLow riskHigh riskInitiation of kidney replacement therapyEffects of glucose-lowering agentsCardiovascular diseaseHigh risk of cardiovascular diseaseAssociated with increased riskBaseline CVD riskAssociated with higher riskRisk of cardiovascular diseaseGlucose-lowering agentsCare of peopleIncident kidney diseaseModerate cardiovascular riskTarget trial framework
2022
1157-P: Mortality among People with Diabetes Experiencing Hypoglycemic and Hyperglycemic Crises
MCCOY R, HERRIN J, SWARNA K, GALINDO R, UMPIERREZ G, GOLDEN S, O'CONNOR P. 1157-P: Mortality among People with Diabetes Experiencing Hypoglycemic and Hyperglycemic Crises. Diabetes 2022, 71 DOI: 10.2337/db22-1157-p.Peer-Reviewed Original ResearchSevere hypoglycemiaPreventable acute complicationEmergency department visitsRelevant patient characteristicsRisk of deathType 2 diabetesHigh-risk individualsType 1 diabetesNovo NordiskRace/ethnicityAdvisory PanelAcute complicationsCause mortalityHyperglycemic crisisPatient characteristicsDepartment visitsKidney diseaseRisk individualsMortality rateSubsequent mortalityHypoglycemiaDiabetesHyperglycemiaMortalityNational Institute898-P: Impact of Switching to a High-Deductible Health Plan on Patients’ Out-of-Pocket Expenditures for Glucose-Lowering Drugs
JIANG D, HERRIN J, VAN HOUTEN H, MCCOY R. 898-P: Impact of Switching to a High-Deductible Health Plan on Patients’ Out-of-Pocket Expenditures for Glucose-Lowering Drugs. Diabetes 2022, 71 DOI: 10.2337/db22-898-p.Peer-Reviewed Original ResearchHigh-deductible health plansGlucose-lowering drugsHDHP enrolleesOOP expensesHealth outcomesPocket expenditureHealth plansBurden of treatmentCostly health conditionsPoor health outcomesDeductible Health PlansGlycemic managementHigh-value careKidney diseaseDiabetes managementOOP costsValue careOOP expenditurePrescription drugsDiabetesHealth conditionsDirect costsDrugsEnrolleesHealth insurance
2021
Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial
Vu K, Zhou J, Everhart A, Desai N, Herrin J, Jena AB, Ross JS, Shah ND, Karaca-Mandic P. Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial. BMC Nephrology 2021, 22: 284. PMID: 34419007, PMCID: PMC8379779, DOI: 10.1186/s12882-021-02491-y.Peer-Reviewed Original ResearchConceptsErythropoiesis-stimulating agentsChronic kidney diseaseEpoetin alfaDarbepoetin alfaTREAT trialTypes of ESAsNew clinical evidencePrimary care physiciansMedicare AdvantageUptake of evidenceCare physiciansAnemia treatmentClinical evidenceKidney diseasePhysician genderMedicare feeUnsafe treatmentSegmented regression approachStudy periodPhysiciansService populationConsistent changesAlfaHigher useTreatment